This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeoStem Welcomes Dr. Adel Nada As Vice President, Immunotherapy

NEW YORK, April 3, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today the appointment of Dr. Adel Nada as Vice President, Immunotherapy. In this position, Dr. Nada will be responsible for developing the Company's T Regulatory Cell Program, which is investigating the use of T Regulatory Cells ("Tregs") to treat diseases caused by imbalances in the immune system. The Company plans to initiate a Phase 2 study of Treg based therapeutics to treat type 1 diabetes in the third quarter of 2014, as well as a Phase 1 study in Canada of Treg based therapeutics in support of a steroid resistant asthma indication in 2014.

"We are very pleased that Dr. Nada has joined us, adding his expertise in immunology and clinical development to the growing NeoStem team," said Dr. Douglas Losordo, Chief Medical Officer of NeoStem. "Dr. Nada's experience strengthens our clinical programs at an important time as we launch new initiatives in diabetes and asthma."

Dr. Nada comes to NeoStem from Baxter Healthcare, where from 2012 to 2014 he was Senior Medical Director, Cardiovascular Cellular Therapies. Prior to joining Baxter, Dr. Nada worked at Abbott Laboratories from 2007-2012 where he was most recently responsible for the Clinical Pharmacology Medical Department. In this capacity, he led the cross functional group that provided instrumental strategic support for early clinical development across the entire company's pipeline. Working across different therapeutic areas, most notably antivirals, oncology, and immunology, he also led the clinical team developing a novel compound for rheumatoid arthritis.

"I am excited to join NeoStem's clinical development team at this key time as the company is planning to initiate two clinical trials for its T Regulatory Cell Program," said Dr. Nada. "I am pleased to bring my broad clinical development expertise to the program to help develop and execute upon the Company's vision for Treg therapies."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs